MYD88 and diffuse large B-cell lymphoma: In a smaller study including six primary OA-DLBCL-NOS patients, MYD88 pathogenic variants were found in a higher proportion of patients (4 of 6, 67%), which may be attributed to the higher percentage of non-GCB patients in this study compared to our study (83% vs. 57%) [21].